

Special Issue

Poor-Risk and Relapsed/Refractory Germ Cell Tumor

Message from the Guest Editor

Germ cell tumors (GCT) belong to the most chemosensitive solid tumors and represent a model for a curable cancer. Cisplatin represents the mainstay in the treatment of GCTs. Cisplatin-based first line chemotherapy can cure about 70–80% of patients with disseminated testicular cancer. Salvage chemotherapy with standard dose cisplatin plus previously not utilized drugs will cure 20–25% of patients who were not initially cured with their induction chemotherapy. Because of insufficient results in the treatment of poor-risk and relapsed/refractory GCTs, evaluation of new treatment strategies and new drugs with significant antitumor activity, as single-agent or combination treatments, remains a priority. Identification of new biomarkers and/or therapeutic targets remains one of the research goals as well. This Special issue of *IJMS* is focused on advances in research of poor-risk and relapsed/refractory testicular germ cell tumor and articles that cover this topic, including preclinical research, biomarker research, and research that focuses on special subpopulations of patients are welcome.

Guest Editor

Prof. Dr. Michal Mego

2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia

Deadline for manuscript submissions

closed (31 January 2022)



International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/56132

*International Journal of
Molecular Sciences*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ijms@mdpi.com

[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)





International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)



About the Journal

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences,
Sez-Biochimica, Faculty of Medicine, Università Politecnica delle
Marche, Via Ranieri 65, 60100 Ancona, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore
- Q1 (Organic Chemistry)